Ibarel is an independent information resource focused on ibogaine research and related questions about safety, evidence, and clinical practice. Our mission is plainspoken and evidence-first: to gather, organize, and explain the literature so people affected by substance use, their families, advocates, and professionals can see what is known — and what remains uncertain.
We collect and explain evidence without advocacy or commercial promotion. Our editorial process prioritizes primary literature, formal registries, and statements from recognized health authorities when available.
Content is assembled from peer-reviewed articles, clinical trial registries, and authoritative public sources. For example, when discussing clinical safety we consult trial registries and published case series rather than relying on anecdote, and we cross-check claims against established guidance such as what large public health bodies publish.
We also link to curated specialist resources when they materially add safety context; one such specialized resource on cardiac risk is available through the ibogaine cardiac project and is cited in focused discussions.
Ibarel organizes material into thematic sections that help readers find vetted evidence and practical context: clinical summaries, safety considerations, research methods, and an annotated guide to the literature. Each section is designed for people seeking clarity — whether a clinician looking for trial details or a family member wanting plain-language summaries.
We maintain a concise overview page and deeper topic pages; the site structure intentionally points readers to services descriptions and background material when a procedural or organizational context is helpful, and we link back to the main site overview in narrative places to keep navigation natural and discoverable.
Content is grouped by topic and evidence level. When clinical safety or procedural detail is discussed, we include direct links to registries or original reports so readers can verify statements themselves.
We follow a short set of principles that guide selection, presentation, and correction of material.
Reliable editorial practice includes citing established public sources when they are relevant. Government health sites and academic pages are typical anchors for safety claims; for clinical trial context we consult registries such as ClinicalTrials.gov and also reference methodological overviews like the discussion of evidence synthesis on Wikipedia when summarizing standard approaches to systematic review.
For instance, when explaining how trials are registered we point readers to the registry platform at ClinicalTrials.gov (ClinicalTrials.gov) and to broader methodological guidance available from academic centers (Harvard T.H. Chan School of Public Health), and to general summaries of systematic review methods on Wikipedia for readers new to evidence synthesis.
Ibarel is an independent information resource, not a clinic, medical provider, or licensed treatment center. Our pages explain evidence and point to primary sources; they do not offer medical or legal advice. If you need clinical care or individualized medical guidance, please consult a licensed healthcare professional or local health authority.
To ensure discoverability and navigational clarity across the site we place inline, contextual links within explanatory paragraphs — for example, to specialist pages and services descriptions — rather than collecting lists of links at the end of articles. This editorial pattern helps readers move from background to practical resources such as the services page where procedural context is described.
We welcome corrections that improve factual accuracy. For editorial inquiries, the Contact page explains how to reach the team and what information to provide; for structural questions about the site you can also see the services descriptions that outline our editorial workflows.
No. Ibarel is an independent information resource and does not provide clinical services or personalized medical advice. See our contact page for editorial questions and the services page for site navigation about available resources: services descriptions.
We prioritize transparent methods: primary reports, registered protocols, and recognized public guidance. When a claim affects safety or clinical interpretation we require traceable sources such as a registry entry or peer-reviewed publication.
Specialized compilations—like projects that document cardiac risk—are linked inline where relevant, for example to a focused cardiac-risk resource we reference in our safety discussions (detailed cardiac-risk analysis).